Fractyl Health, Inc. (GUTS)

$2.64

-0.15

(-5.38%)

Market is closed - opens 7 PM, 17 Sep 2024

Performance

  • $2.60
    $2.85
    $2.64
    downward going graph

    1.52%

    Downside

    Day's Volatility :8.77%

    Upside

    7.37%

    downward going graph
  • $1.74
    $14.50
    $2.64
    downward going graph

    34.09%

    Downside

    52 Weeks Volatility :88.0%

    Upside

    81.79%

    downward going graph

Returns

PeriodFractyl Health, Inc.Index (Russel 2000)
3 Months
-51.29%
0.0%
6 Months
-57.76%
0.0%
1 Year
-79.46%
0.0%
3 Years
-79.46%
-20.9%

Highlights

Market Capitalization
133.7M
Book Value
$1.48
Earnings Per Share (EPS)
-1.37
Wall Street Target Price
15.5
Profit Margin
0.0%
Operating Margin TTM
-53453.49%
Return On Assets TTM
-48.23%
Return On Equity TTM
-169.24%
Revenue TTM
119.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-40.300000000000004%
Gross Profit TTM
0.0
EBITDA
-71.0M
Diluted Eps TTM
-1.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Fractyl Health, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 487.12%

Current $2.64
Target $15.50

Technicals Summary

Sell

Neutral

Buy

Fractyl Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fractyl Health, Inc.
Fractyl Health, Inc.
-2.94%
-57.76%
-79.46%
-79.46%
-79.46%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-3.66%
20.12%
39.85%
76.89%
300.21%
Novo Nordisk A/s
Novo Nordisk A/s
1.22%
3.02%
46.72%
169.99%
437.18%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-1.5%
83.41%
50.4%
42.05%
207.87%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.28%
18.97%
39.04%
159.92%
178.09%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fractyl Health, Inc.
Fractyl Health, Inc.
NA
NA
NA
0.0
-1.69
-0.48
NA
1.48
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.57
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
46.28
46.28
2.09
3.43
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fractyl Health, Inc.
Fractyl Health, Inc.
Buy
$133.7M
-79.46%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$127.1B
300.21%
30.58
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$606.9B
437.18%
46.28
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.1B
207.87%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.3B
178.09%
32.84
-4.74%

Company Information

Organization
Fractyl Health, Inc.
Employees
112
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Industry
Miscellaneous

FAQs